SAB BIOTHERAPEUTICS, INC. Interest Expense
SAB BIOTHERAPEUTICS, INC. (SABS) reported Interest Expense of $93.12 thousand for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-08.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-08-08
- SAB BIOTHERAPEUTICS, INC. interest expense for the quarter ending 2024-06-30 was $93.12K, a 23.63% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. interest expense for the quarter ending 2024-03-31 was $76.37K, a 17.33% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. interest expense for the quarter ending 2023-12-31 was $77.88K, a 11.20% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. interest expense for the quarter ending 2023-09-30 was $69.70K, a 1.31% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. interest expense for fiscal 2023 was $315.28K, a 4.54% increase from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. interest expense for fiscal 2022 was $301.58K, a 2.42% increase from fiscal 2021.
- SAB BIOTHERAPEUTICS, INC. interest expense for fiscal 2021 was $294.46K, a 37.24% decline from fiscal 2020.
- SAB BIOTHERAPEUTICS, INC. interest expense for fiscal 2020 was $469.15K.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 6 month as first filed | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|---|---|
| 2024-06-30 | $93.12K 10-Q · filed 2024-08-08 | $169.49K 10-Q · filed 2024-08-08 | $247.37K derived: sum of 3 quarters · filed 2024-08-08 | $317.07K derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2024-03-31 | $76.37K 10-Q · filed 2024-05-20 | $154.25K derived: sum of 2 quarters · filed 2024-05-20 | $223.95K derived: sum of 3 quarters · filed 2024-05-20 | $299.27K derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-12-31 | $77.88K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $147.58K derived: sum of 2 quarters · filed 2024-03-29 | $222.90K derived: sum of 3 quarters · filed 2024-08-08 | $315.28K 10-K · filed 2024-03-29 | ||
| 2023-09-30 | $69.70K 10-Q · filed 2023-11-13 | $145.02K derived: sum of 2 quarters · filed 2024-08-08 | $237.41K 10-Q · filed 2023-11-13 | $325.10K derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-06-30 | $75.32K 10-Q · filed 2024-08-08 | $167.71K 10-Q · filed 2024-08-08 | $255.40K derived: sum of 3 quarters · filed 2024-08-08 | $326.03K derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $92.39K 10-Q · filed 2024-05-20 | $180.08K derived: sum of 2 quarters · filed 2024-05-20 | $250.71K derived: sum of 3 quarters · filed 2024-05-20 | $321.95K derived: sum of 4 quarters · filed 2024-05-20 | ||
| 2022-12-31 | $87.70K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $158.32K derived: sum of 2 quarters · filed 2024-03-29 | $229.56K derived: sum of 3 quarters · filed 2024-03-29 | $301.58K 10-K · filed 2024-03-29 | ||
| 2022-09-30 | $70.63K 10-Q · filed 2023-11-13 | $141.86K derived: sum of 2 quarters · filed 2023-11-13 | $213.88K 10-Q · filed 2023-11-13 | $280.16K derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $71.24K 10-Q · filed 2023-08-21 | $143.26K 10-Q · filed 2023-08-21 | $209.53K derived: sum of 3 quarters · filed 2023-08-21 | $288.09K derived: sum of 4 quarters · filed 2023-08-21 | ||
| 2022-03-31 | $72.02K 10-Q · filed 2023-05-15 | $138.30K derived: sum of 2 quarters · filed 2023-05-15 | $216.85K derived: sum of 3 quarters · filed 2023-05-15 | $291.29K derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $66.28K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-28 | $144.83K derived: sum of 2 quarters · filed 2023-04-28 | $219.27K derived: sum of 3 quarters · filed 2023-04-28 | $294.46K 10-K/A · filed 2023-04-28 | ||
| 2021-09-30 | $78.56K 10-Q · filed 2022-11-14 | $152.99K derived: sum of 2 quarters · filed 2022-11-14 | $228.18K 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $74.43K 10-Q · filed 2022-08-10 | $2.90K 10-Q · filed 2021-08-09 | $149.63K 10-Q · filed 2022-08-10 | $5.32K 10-Q · filed 2021-08-09 | ||
| 2021-03-31 | $75.19K 10-Q · filed 2022-05-12 | $2.42K 10-Q · filed 2021-05-21 | ||||
| 2020-12-31 | $469.15K 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |